Did you know?

ChinaBio® Group is a consulting and advisory firm helping life science companies and investors achieve success in China. ChinaBio works with U.S., European and APAC companies and investors seeking partnerships, acquisitions, novel technologies and funding in China.  

Learn more >>

Free Newsletter

Have the latest stories on China's life science industry delivered to your inbox daily or weekly - free!

See preview >>

  Email address:
   

InxMed Starts Pivotal Trial of FAK Inhibitor for Resistant Ovarian Cancer

publication date: Sep 8, 2022

Nanjing InxMed has started a pivotal China Phase II trial of its lead drug, a selective oral inhibitor of focal adhesion kinase (FAK), in patients with platinum-resistant recurrent ovarian cancer (PROC). InxMed develops innovative therapies that target drug resistance and metastasis in hard-to-treat solid tumors. The Phase II study will test IN10018 in combination with pegylated liposomal doxorubicin (PLD) in patients with PROC. At ASCO 2022, InxMed reported the combination regimen showed antitumor efficacy and a good safety profile in PROC patients. More details....

Share this with colleagues:  



Sorry this page is available to subscribers only.
If you're not a subscriber why not subscribe today?

If you are already a subscriber, please login.

If you believe you should have received this message in error, please contact us.


 

To gain access to the members only content click here to subscribe.

You will be given immediate access to premium content on the site.

Upcoming Events

ChinaBio® Partnering Forum
September 10–11, 2024 | Shanghai, China
Register here

BIO-Europe®
November 4–6, 2024 | Stockholm, Sweden
Save €900 before September 13!
Register here

Biotech Showcase™
January 13–15, 2025 | San Francisco, CA
Save $600 before September 27!
Other Relevant Events

Antibody Engineering & Therapeutics Asia
October 21–23, 2024 | Kyoto, Japan
Save 30% with code CHINABIO30!
Register here